Larvol Delta - aTyr-Pharma-Announces-Phase-2-Study-of-Efzofitimod-in-Patients-with-Systemic-SclerosisAssociated-Interstitial-Lung-Disease-SScILD-Following-FDA-Clearance-of-IND-Application

Stalaris (efzofitimod) - aTyr Pharma, Kyorin

https://www.biospace.com/article/releases/atyr-pharma-announces-phase-2-study-of-efzofitimod-in-patients-with-systemic-sclerosis-associated-interstitial-lung-disease-ssc-ild-following-fda-clearance-of-ind-application/

Mar 1, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next